These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Deacon CF; Mannucci E; Ahrén B Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248 [TBL] [Abstract][Full Text] [Related]
4. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Vergès B; Bonnard C; Renard E Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]
6. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Morales J Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467 [TBL] [Abstract][Full Text] [Related]
7. Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure? Packer M J Card Fail; 2018 Feb; 24(2):109-111. PubMed ID: 29305970 [No Abstract] [Full Text] [Related]
8. The entero-insular axis: implications for human metabolism. Ranganath LR Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966 [TBL] [Abstract][Full Text] [Related]
9. Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure. Takahashi A; Ihara M; Yamazaki S; Asanuma H; Asakura M; Kitakaze M Int Heart J; 2015; 56(4):372-6. PubMed ID: 26104180 [TBL] [Abstract][Full Text] [Related]
10. Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena. AlAnazi FH; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Ogaly HA; Alanazi YA; Saad HM; Batiha GE J Diabetes; 2023 May; 15(5):397-408. PubMed ID: 37078106 [TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Tzefos M; Harris K; Brackett A Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of incretins in diabetes. Advani A; Bugyei-Twum A; Connelly KA Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557 [TBL] [Abstract][Full Text] [Related]
13. The effects of glucagon-like peptide-1 on the beta cell. Vilsbøll T Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257 [TBL] [Abstract][Full Text] [Related]
14. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Fineman MS; Cirincione BB; Maggs D; Diamant M Diabetes Obes Metab; 2012 Aug; 14(8):675-88. PubMed ID: 22233527 [TBL] [Abstract][Full Text] [Related]
15. Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with Esser N; Mongovin SM; Parilla J; Barrow BM; Mundinger TO; Fountaine BS; Larmore MJ; Castillo JJ; Akter R; Hull RL; Zraika S Am J Physiol Endocrinol Metab; 2022 Mar; 322(3):E307-E318. PubMed ID: 35128957 [TBL] [Abstract][Full Text] [Related]
16. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. Neumiller JJ J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361 [TBL] [Abstract][Full Text] [Related]
17. BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus. Ding L; Lu S; Wang Y; Chen H; Long W; Ma C; He E; Yan D; Tan F Pharmacol Res; 2017 Aug; 122():130-139. PubMed ID: 28619366 [TBL] [Abstract][Full Text] [Related]